Her Highness Sheikha Moza bint Nasser Inaugurates Pediatric Stem Cell Transplant Ward at Sidra Medicine
Sidra Medicine, a member of Qatar Foundation, proudly announces the official inauguration of its state-of-the-art Pediatric Hematopoietic Stem Cell Transplant (HSCT) Ward, launched under the patronage of Her Highness Sheikha Moza bint Nasser.
This marks a groundbreaking advancement in Qatar’s pediatric healthcare landscape — the country’s first dedicated ward offering bone marrow transplant services to children with complex blood disorders, genetic diseases, and immune system conditions.
Specialised Care for Our Youngest Patients
The new HSCT Ward is designed exclusively for patients under 18 years of age, delivering highly specialised care for conditions such as:
- Leukemia and lymphoma
- Thalassemia and sickle cell disease
- Immune deficiencies
- Metabolic and rare genetic disorders
Treatments include autologous (self-donated) and allogeneic (donor-based) hematopoietic stem cell transplants, also known as bone marrow transplants.
Precision Medicine Meets Global Standards
Sidra Medicine’s HSCT program is a cornerstone of its precision medicine strategy. The new ward features:
- 20-bed capacity designed for HSCT and hematology-oncology inpatients
- High-level isolation facilities that meet global infection control standards
- Access to Good Manufacturing Practice (GMP)-certified stem cell processing and cryopreservation
- A multidisciplinary care team including hematologists, oncologists, immunologists, psychologists, pharmacists, nutritionists, and child life experts
Building Qatar’s Future in Regenerative Medicine
This launch supports Qatar’s healthcare goals under Qatar National Vision 2030, including:
- Reducing outbound patient referrals
- Expanding regional access to advanced therapies
- Developing national expertise in cell and gene therapies
As of mid-2025, the HSCT ward will begin autologous transplants, with preparations underway for allogeneic procedures. Future phases will include CAR-T cell therapies and Casgevy gene therapy for thalassemia and sickle cell disease.
💬 Leadership Voices
Dr. Iyabo Tinubu-Karch, CEO of Sidra Medicine:
“The HSCT program strengthens our commitment to providing world-class, family-centered care—right here in Qatar.”
Prof. Ibrahim Janahi, Chief Medical Officer:
“This initiative is a major step toward building a knowledge-based, innovation-driven health system in line with Qatar’s national goals.”
Serving Local & International Families
The HSCT Program at Sidra Medicine is open to both Qatari and international patients. More than 50 children are currently awaiting transplantation, and new patient referrals are now being accepted.
To learn more about our Pediatric Hematology, Oncology, and HSCT services, or to refer a patient, please visit:
🔗 www.sidra.org
